MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.390
AS - Asia 5.964
EU - Europa 4.085
SA - Sud America 935
AF - Africa 104
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 5
Totale 21.516
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.218
SG - Singapore 2.094
CN - Cina 1.615
GB - Regno Unito 938
IT - Italia 806
BR - Brasile 718
HK - Hong Kong 711
VN - Vietnam 638
FI - Finlandia 489
SE - Svezia 387
DE - Germania 384
RU - Federazione Russa 245
FR - Francia 216
KR - Corea 197
UA - Ucraina 147
TR - Turchia 135
NL - Olanda 95
BG - Bulgaria 89
AR - Argentina 85
ID - Indonesia 85
IN - India 83
BD - Bangladesh 66
JP - Giappone 65
CA - Canada 59
AT - Austria 56
MX - Messico 56
IQ - Iraq 54
AE - Emirati Arabi Uniti 36
ES - Italia 32
PL - Polonia 32
AU - Australia 30
EC - Ecuador 30
ZA - Sudafrica 30
IE - Irlanda 29
PK - Pakistan 29
CL - Cile 25
LT - Lituania 23
MA - Marocco 23
VE - Venezuela 22
BZ - Belize 20
CO - Colombia 20
BE - Belgio 18
UZ - Uzbekistan 18
PH - Filippine 16
KW - Kuwait 14
PT - Portogallo 14
CZ - Repubblica Ceca 13
PE - Perù 13
CH - Svizzera 12
HU - Ungheria 12
NP - Nepal 12
MY - Malesia 11
SA - Arabia Saudita 11
DZ - Algeria 10
DO - Repubblica Dominicana 9
KE - Kenya 9
TH - Thailandia 9
TW - Taiwan 9
AZ - Azerbaigian 8
KG - Kirghizistan 8
PY - Paraguay 8
EG - Egitto 7
UY - Uruguay 7
AL - Albania 6
IL - Israele 6
JO - Giordania 6
RO - Romania 6
TN - Tunisia 6
EE - Estonia 5
EU - Europa 5
GR - Grecia 5
GT - Guatemala 5
LV - Lettonia 5
PR - Porto Rico 5
IR - Iran 4
SN - Senegal 4
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
DK - Danimarca 3
GY - Guiana 3
JM - Giamaica 3
KH - Cambogia 3
LB - Libano 3
MT - Malta 3
NZ - Nuova Zelanda 3
OM - Oman 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CI - Costa d'Avorio 2
CU - Cuba 2
ET - Etiopia 2
KZ - Kazakistan 2
NI - Nicaragua 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
Totale 21.488
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.494
Singapore 1.260
Fairfield 1.026
Ashburn 1.024
Hong Kong 702
Hefei 586
Woodbridge 574
San Jose 527
Houston 470
Southend 461
Seattle 442
Chandler 438
Helsinki 433
Wilmington 323
Cambridge 305
London 293
Beijing 267
Ann Arbor 255
Nyköping 235
Ho Chi Minh City 226
Jacksonville 209
The Dalles 204
Dearborn 193
Seoul 193
Modena 178
New York 176
Munich 145
Council Bluffs 142
Los Angeles 141
Hanoi 137
Lauterbourg 113
Chicago 101
San Diego 101
Dallas 100
Moscow 98
Milan 82
Princeton 78
Sofia 78
São Paulo 71
Buffalo 69
Shanghai 63
Jakarta 54
Eugene 51
Salt Lake City 42
Tokyo 40
Nuremberg 39
Bologna 37
Izmir 37
Redondo Beach 37
Amsterdam 36
Columbus 35
Rio de Janeiro 35
Kent 34
Orem 34
Frankfurt am Main 30
Haiphong 30
Redwood City 29
Dublin 27
Boardman 26
Da Nang 24
Elk Grove Village 24
Brooklyn 22
Guangzhou 22
Florence 21
Mexico City 21
Belize City 20
Rome 20
Vienna 20
Atlanta 19
Johannesburg 19
Lappeenranta 19
Reggio Emilia 19
Brasília 18
Toronto 18
Brussels 17
Chennai 17
Baghdad 16
Tashkent 16
Warsaw 16
Ankara 15
Denver 15
Kilburn 15
Portsmouth 15
Kuwait City 14
Montreal 14
Phoenix 14
Quito 14
Delft 13
Falls Church 13
Paris 13
Porto Alegre 13
Tampa 13
Las Vegas 12
Mumbai 12
Norwalk 12
Parma 12
Thái Bình 12
Istanbul 11
Lahore 11
Melbourne 11
Totale 15.328
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 325
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 316
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 304
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 302
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 290
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 277
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 275
Biotherapies in large vessel vasculitis 274
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 274
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 273
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 272
Imaging of vasculitis: State of the art 272
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 267
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 266
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 263
Biologics in vasculitides: Where do we stand, where do we go from now? 258
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 257
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 252
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 252
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 252
Increased expression of interleukin-22 in patients with giant cell arteritis 249
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 242
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 239
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 236
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 235
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 233
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 229
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 229
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 227
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 225
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 224
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 223
Updates on the diagnosis and monitoring of giant cell arteritis 218
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 216
Statin use in giant cell arteritis: a retrospective study 215
Large-vessel giant cell arteritis: a cohort study 213
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 213
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 211
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 210
Tocilizumab for the treatment of giant cell arteritis 210
Mycophenolate mofetil in primary central nervous system vasculitis 210
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 209
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 200
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 197
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 197
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 192
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 191
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 188
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 188
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 186
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 185
L30. Assessment of vasculitis extent and severity 182
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 181
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 178
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 176
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 174
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 174
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 173
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 173
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 172
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 171
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 167
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 164
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 164
Giant Cell Arteritis and Polymyalgia Rheumatica 162
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 159
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 159
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 158
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 156
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 156
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 156
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 155
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 153
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 153
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 146
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 145
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 145
Development of the Takayasu Arteritis Integrated Disease Activity Index 143
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 143
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 142
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 141
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 140
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 139
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 139
What to Know About Biopsy Sampling and Pathology in Vasculitis? 136
Eosinophilic giant cell arteritis: A different subset of disease? 136
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 134
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 134
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 134
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 133
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 133
Role of miR-146a and miR-146b in Giant Cell Arteritis. 132
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 129
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 129
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 128
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 127
IgG4-associated sclerosing mesenteritis 125
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 124
Trattamento con Tocilizumab in monoterapia dopo trattamento con glucocorticoidi per breve periodo in pazienti con arterite a cellule giganti con coinvolgimento dei grandi vasi: effetti sui checkpoint immunitari solubili 123
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 122
Totale 19.479
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021260 0 0 0 0 0 0 0 0 0 0 142 118
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20267.750 652 414 774 873 960 612 1.203 451 955 684 172 0
Totale 21.733